Investigational Drug Information for Hematoporphyrin
✉ Email this page to a colleague
What is the drug development status for Hematoporphyrin?
Hematoporphyrin is an investigational drug.
There have been 9 clinical trials for Hematoporphyrin.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2005.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Pleural Diseases. The leading clinical trial sponsors are Roswell Park Cancer Institute, National Cancer Institute (NCI), and Eastern Virginia Medical School.
Summary for Hematoporphyrin
US Patents | 0 |
International Patents | 0 |
US Patent Applications | 2,803 |
WIPO Patent Applications | 1,592 |
Japanese Patent Applications | 50 |
Clinical Trial Progress | Phase 3 (2005-03-01) |
Vendors | 50 |
Recent Clinical Trials for Hematoporphyrin
Title | Sponsor | Phase |
---|---|---|
An Exploratory Clinical Study of Photodynamic Therapy Combined With Sonodynamic Therapy in Cholangiocarcinoma | Second Affiliated Hospital of Guangzhou Medical University | N/A |
Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease | Roswell Park Cancer Institute | Phase 1 |
Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery | National Cancer Institute (NCI) | Phase 1 |
Clinical Trial Summary for Hematoporphyrin
Top disease conditions for Hematoporphyrin
Top clinical trial sponsors for Hematoporphyrin
US Patents for Hematoporphyrin
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |